Interestingly, animal models for ARHR and XLH with primary FGF23 elevations show deficiencies in skeletal muscle fiber contraction and develop muscle weakness, which is ameliorated after injections of an FGF23-blocking antibody (196, 255). The gene discussed is FGF23; the disease is autosomal recessive hypophosphatemic rickets.